Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...

Net sales of Cobenfy, whose success is imperative for Bristol Myers, totaled $27 million in the first quarter, handily ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of exclusivity, has hit a phase 3 setback. Cobenfy as an adjunctive ...

The drug, Cobenfy, was approved last year based on data from three randomized studies comparing the drug to placebo. It was the first new mechanism-of-action approved for schizophrenia in decades.

Cobenfy, already approved to treat schizophrenia ... The trial would have supported a broader approval for the drug.

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a trial designed to expand the label of the recently approved drug failed.

D.J. became one of the first in line to try the new antipsychotic, called Cobenfy — a potentially life-changing drug for one of psychiatry’s most intractable mental illnesses, but whose long ...

Bristol Myers Squibb’s schizophrenia drug Cobenfy brought in $27 million in net sales in the first three months of the year — beating Wall Street sales expectations and analyst predictions.

April 22 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly watched late-stage trial that ...

For around 70 years, the treatment of schizophrenia has relied almost entirely on drugs that block dopamine receptors, so Cobenfy's action on cholinergic receptors offers a brand new way to treat ...

We chat about the recent bounceback in biotech stocks, disappointing results from Bristol Myers Squibb’s schizophrenia drug Cobenfy, new allegations about entrepreneur Sam Waksal, and more.

The drug, Cobenfy, was approved last year based on data from three randomized studies comparing the drug to placebo. It was the first new mechanism-of-action approved for schizophrenia in decades.